

Haematologica  
HAEMATOL/2015/128710  
Version 3

The addition of Rituximab to Fludarabine and Cyclophosphamide chemotherapy results in a significant improvement in overall survival in patients with newly diagnosed mantle cell lymphoma: results of a randomized UK National Cancer Research Institute trial

Disclosures: Cancer Research UK provided the funding to run this trial and Roche provided free Rituximab. Conflicts of interest SR, PJ, JS, DL, JW Roche advisory board members and Roche honoraria. SB, CP, GF Roche honoraria. PH Honoraria and research funding from Roche. AJ Contractor for Roche and research agreement with Genentech Inc.

Contributions: SR was the chief investigator and takes primary responsibility for the paper, PJ, SJ and DL helped design the study, PS, JG and MT co-ordinated the research, AK performed the statistical analysis, AJ performed the laboratory analysis, SB, GF, PH, AK, CP, JS, and JW recruited patients.